Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous Serum Eye Drops Combined With Silicone Hydrogel Lenses for Corneal Epithelial Defects
NCT02291731Completed
- Sponsor
- E-Da Hospital
- Start
- Sep 2014
- Primary completion
- Aug 2015
- Modality
- Biologic
- Countries
- 1
01
Overview
Randomised, open-label trial of Autologous serum eye drops 20% in persistent corneal epithelial defect (PED) (2 arms), sponsored by E-Da Hospital. Primary endpoint: epithelial defect healing rate at 2 weeks. Started Sep 2014; status: completed.
02
Drugs
Autologous serum eye drops 20%
03
Conditions
persistent corneal epithelial defect (PED)
Beyond the preview
Go deeper on NCT02291731.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02291731.